Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
78.59
+0.47 (+0.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
55
56
Next >
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
August 11, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
This Analyst Says Zentalis' Increased Focus On WEE1 Program Is 'Prudent', Slashes Price Target By 37%
August 10, 2022
Via
Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Avalo Therapeutics, Apollo Therapeutics Ink Pact For Anti-IL-18 Antibody
August 01, 2022
Via
Benzinga
Recap: AstraZeneca Q2 Earnings
July 29, 2022
AstraZeneca (NASDAQ:AZN) reported its Q2 earnings results on Friday, July 29, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
AstraZeneca Boosts 2022 Sales Outlook, Citing Covid Treatments
July 29, 2022
The company cited the contribution from its Covid drugs as part of its guidance boost.
Via
Investor's Business Daily
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
August 09, 2022
Via
Benzinga
Recap of Monday's Biotech Catalysts - End Of the Day Summary
August 08, 2022
Via
Benzinga
Lyme Disease And Climate Change Reinvigorates Valneva's Vaccine Efforts After COVID Shot Disappointment
August 08, 2022
Valneva SE (NASDAQ: VALN) is trying to come back after a disappointing COVID-19 shot by betting on the Lyme disease vaccine. Climate change is spurring more cases of tick-borne Lyme disease.
Via
Benzinga
The Power of Science to Stop a Killer
August 08, 2022
Via
Investor Brand Network
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
August 08, 2022
An estimated 200 million Americans — more than 60% of the population — suffer from at least one neurological disorder. That includes dementia, strokes, migraines and other diseases or infections that...
Via
Benzinga
The Power of Science to Stop a Killer
August 08, 2022
NetworkNewsWire Editorial Coverage New York, NY – August 8, 2022 – Nearly half of all American adults suffer from hypertension (high blood pressure), often referred to as a silent killer. More than 114...
Via
FinancialNewsMedia
AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting
August 08, 2022
Via
Benzinga
TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
August 08, 2022
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
August 05, 2022
From
AstraZeneca
Via
Business Wire
CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications
August 05, 2022
From
AstraZeneca
Via
Business Wire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 04, 2022
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients...
Via
Benzinga
Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs
August 04, 2022
Via
Benzinga
AstraZeneca and Merck Receives European Commission Approval For Expanded Use In Breast Cancer Therapy
August 04, 2022
The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients...
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
3 Pharma Stocks' Post-Earnings Price Moves
August 04, 2022
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
Emergent BioSolutions Posts Q2 Loss On Lower Sales, Q3 Forecasts Below Consensus
August 02, 2022
Via
Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
August 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
August 01, 2022
Via
Benzinga
3-D Portfolio: Discounts, Diversification, And Dividends
July 31, 2022
When it comes to high-yield closed-end funds, I’m a big fan of the “three Ds” — discounts, diversification, and dividends. Today, we’ll look at a three-fund, bargain-priced “3-D” CEF portfolio you can...
Via
Talk Markets
AstraZeneca Drops Moderna-Partnered, Phase 2 Heart Disease Drug Candidate
July 29, 2022
AstraZeneca Plc (NASDAQ: AZN) has removed a Moderna Inc (NASDAQ: MRNA)-partnered cardiovascular disease candidate from its phase 2 pipeline.
Via
Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
July 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review
July 29, 2022
The major indexes made big moves amid key earnings and another big Fed rate hike.
Via
Investor's Business Daily
Benzinga Before The Bell: Apple's Strong China Revenue, Amazon's EV Partnership, Jack Ma To Cede Control Of Ant Financial And Other Top Financial Stories Friday, July 29
July 29, 2022
Reuters Tencent’s Overseas Ambitions Face Resistance From India
Via
Benzinga
AstraZeneca Q2 Highlights: Profits Fall, COVID-19 Vaccine Sales Dip, Lifts Annual Sales Guidance
July 29, 2022
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.